Consistent Intraocular Pressure Reduction by Solid Drug Nanoparticles in Fixed Combinations for Glaucoma Therapy
Da Huang,Pedro Norat,Lin Qi,Anna Chernatynskaya,James D. Cole,Vimalin Jeyalatha Mani,Lei Xu,Xiaorong Liu,Hu Yang
DOI: https://doi.org/10.1002/advs.202401648
IF: 15.1
2024-06-16
Advanced Science
Abstract:Using a scalable method for fabricating solid drug nanoparticles (SDNs), SDNs in fixed combination of the hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX) are consistently produced. These SDNs demonstrated enhanced ocular permeation and sustained intraocular pressure reduction, indicating their effectiveness for glaucoma therapy. Efficient topical drug delivery remains a significant challenge in glaucoma management. Although nanoparticle formulations offer considerable promise, their complex preparation processes, co‐delivery issues, and batch consistency have hindered their potential. A scalable fabrication strategy is developed here for preparing solid drug nanoparticles (SDNs) with enhanced drug delivery efficiency. Utilizing hydrophobic antiglaucoma drugs brimonidine (BM) and betaxolol (BX), uniform fixed combination BM/BX SDNs are fabricated through a continuous process, improving batch‐to‐batch consistency for combined glaucoma treatment. With trehalose being used as a lyoprotectant, BM/BX SDNs can be stored as dry powder and easily reconstituted in phosphate buffered saline. Importantly, reconstituted BM/BX SDNs form clear, homogenous solutions, and exhibit negligible cytotoxicity and irritation, making them well‐suited for topical administration as eyedrops. Ex vivo and in vivo studies demonstrated that topically applied BM/BX SDNs permeate through the cornea significantly (about two fold to three fold) compared to their hydrophilic counterparts, i.e., brimonidine tartrate, and betaxolol hydrogen chloride. Notably, BM/BX SDNs displayed consistent intraocular pressure lowering effects in vivo in both normotensive rats and glaucoma mice. Collectively, this study demonstrates the potential of the scalable fabrication strategy and the resultant BM/BX SDNs for improving glaucoma management through eyedrops.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry